ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LRMR
BCYC (20) GLSI (31) AMRN (32) ABEO (23) ⌘ Pro Terminal →

Larimar Therapeutics Inc. (LRMR) — RQD Stock Rating Cockpit

$2.37 -4.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.35

Larimar Therapeutics Inc. (LRMR) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $256.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LRMR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LRMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Larimar Therapeutics Inc. (NASDAQ: LRMR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.37 (-4.05% 1D, market cap $256.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LRMR ranks #628 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LRMR compare to BCYC and GLSI in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LRMR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCYC (Bicycle Therapeutics plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $256.5M) and GLSI (Greenwich LifeSciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $255.5M). Among the 5-stock peer group, LRMR leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LRMR?
▼

Per LRMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374690), Larimar Therapeutics Inc. generated $483.0M in revenue (+89.8% YoY), -$165.7M in net income, and -$113.3M in free cash flow against $145.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.35 (-0.92%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D
Cash (8)Whales (3)SEC (10)Macro (8)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11% Base Target
$7 Bull$2 Base$2 Bear
📬 FREE LRMR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LRMR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY LRMR SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$2.16+13% Next Q
Q2 (-2Q)
29
Grade E$2.44-2% Next Q
Q3 (-1Q)
31
Grade E$2.39-0.8% Next Q
Current
34
Grade E$2.37-8.7% Hist 90D α
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LRMR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LRMR currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.15) and Max Pain ($2.49) forces dealer call-delta covering toward $6.74.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LRMR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LRMR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
44.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE10% OF RANGE
L: $2$2.37H: $6
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 8 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 18 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on LRMR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

8/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like LRMR
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LRMR)

  • ✓Walkthrough of LRMR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LRMR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -43.84%📐 HORIZONTAL RANGE
2026-11-03O $2.67H $2.67L $2.37C $2.37VOL 781.3K
RES: $4.63SUP: $1.76SMA50: $3.15SMA200: $3.80
$4.98$4.15$3.32$2.48$1.65RES $4.63SUP $1.76$2.372026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LRMR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LRMR Butterfly Map → + Track LRMR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +89.8% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LRMR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LRMR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LRMR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LRMR)

Health Care Rank #628 of 1015 ⚔️ BCYC vs LRMR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LRMR vs. BCYC, GLSI, AMRN, ABEO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Larimar Therapeutics Inc. (LRMR) ranks #628 by composite RQD confidence (34/100, grade E) and #534 by equity capitalization ($256.6M). Within this direct 5-issuer industry benchmark cohort, LRMR leads on earnings valuation at N/A trailing P/E, while AMRN leads on capital efficiency and profitability with -12.2% ROIC and 56.6% gross margin. LRMR currently leads its immediate peer cohort in composite quantitative strength at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LRMR ACTIVE
Larimar Therapeutics Inc.
E 34/100 — — -35.0% -4.05% $256.6M Benchmark Subject
BCYC
Bicycle Therapeutics plc
E 20/100 — — -35.0% -1.09% $256.5M /bcyc-vs-lrmr →
GLSI
Greenwich LifeSciences Inc.
E 31/100 — — -35.0% -5.46% $255.5M /glsi-vs-lrmr →
AMRN
Amarin Corporation plc
E 32/100 — 56.6% -12.2% +0.17% $249.9M /amrn-vs-lrmr →
ABEO
Abeona Therapeutics Inc.
E 23/100 — 73.7% -35.0% -2.30% $248.8M /abeo-vs-lrmr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001374690 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Larimar Therapeutics Inc. (LRMR) reported GAAP revenue of $483.0M (+89.8% vs. FY2024 revenue of $254.5M , and +313.1% cumulative change since FY2023) , GAAP net income of -$165.7M, operating cash flow of -$113.2M, and free cash flow of -$113.3M (-59.0% YoY). On the balance sheet, LRMR closed FY2025 with $145.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $483.0M -$165.7M -$113.2M -$113.3M $145.8M —
FY2024 (FY) 2024-12-31 $254.5M -$80.6M -$70.8M -$71.3M $200.2M —
FY2023 (FY) 2023-12-31 $116.9M -$36.9M -$33.5M -$33.5M — —

3. LRMR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LRMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Larimar Therapeutics Inc. (NASDAQ: LRMR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $2.37 (-4.05% 1D, market cap $256.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, LRMR ranks #628 in composite RQD confidence.

How does LRMR compare to BCYC and GLSI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LRMR carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, BCYC (Bicycle Therapeutics plc) holds a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $256.5M) and GLSI (Greenwich LifeSciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $255.5M). Among the 5-stock peer group, LRMR leads on earnings multiple (N/A) while AMRN leads on capital efficiency (-12.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LRMR?

Per LRMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001374690), Larimar Therapeutics Inc. generated $483.0M in revenue (+89.8% YoY), -$165.7M in net income, and -$113.3M in free cash flow against $145.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LRMR trading relative to its 50-day, 200-day, and 52-week technical levels?

LRMR last traded at $2.37 (-4.05% on volume of 667,741 shares), positioning the stock -24.76% below its 50-day simple moving average ($3.15) and -37.63% below its 200-day simple moving average ($3.80). Across its 52-week range of $1.91 to $6.42, LRMR sits at the 10.2% percentile with a 14-day RSI of 44.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.07 to $2.67).

Direct Sub-Reports: LRMR RQD Cockpit LRMR 12M Forecast LRMR Earnings & Move LRMR Dividends & DRIP LRMR Insiders & 13F LRMR Whale Options LRMR Profit Sankey LRMR News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

LRMR — Larimar Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Larimar Therapeutics Inc. (LRMR) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.37 (-4.05% 1D, market capitalization $256.6M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sector is Health Care and industry is Biotechnology: Pharmaceutical Preparations. The profile lists the company as NASDAQ-listed.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Larimar Therapeutics Inc. (LRMR) reported $483.0M in annual revenue (up from $254.5M in FY2024, +89.8% YoY) and -$165.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($116.9M revenue, -$36.9M net income) through FY2025, LRMR scaled operating cash flow to -$113.2M and free cash flow to -$113.3M, backed by $145.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.91 – $6.42 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), LRMR carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can LRMR sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $483.0M and free cash flow of -$113.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is LRMR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LRMR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Larimar Therapeutics Inc. (LRMR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LRMR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LRMR Bull vs. Bear Conversation Board — What's Your Call at $2.37?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LRMR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LRMR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $3.16 (+27.9%)
📌 Pinned Debate

Recent news wire items cite a $14.89 12-month price target implying 451% upside, with cash rising to $85.4M in FY 2025.

Picked up a starter position in LRMR in my $100K Virtual Cash book at $2.47. Recent news wire items cite a $14.89 12-month price target implying 451% upside, with cash rising to $85.4M in FY 2025.. Trading inside a $1.91–$6.42 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $2.03 (-17.8%)
Spot @ $2.47

Operating losses widened to -$172.5M in FY 2025 with zero reported revenue, ROIC at -35%, and a Piotroski F-Score of 2/9.

Fading this rally in LRMR at $2.47. Operating losses widened to -$172.5M in FY 2025 with zero reported revenue, ROIC at -35%, and a Piotroski F-Score of 2/9.. With a beta of 1.0 and the stock sitting at $2.47 (52-wk range $1.91–$6.42), the easy multiple expansion is already priced in.

LIVE TAPE